BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34729266)

  • 1. The Role of Avapritinib for the Treatment of Systemic Mastocytosis.
    Sumbly V; Landry I; Iqbal S; Bhatti Z; Alshamam MS; Ashfaq S; Rizzo V
    Cureus; 2021 Sep; 13(9):e18385. PubMed ID: 34729266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avapritinib for Systemic Mastocytosis.
    Bose P; Verstovsek S
    Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Medicine in Systemic Mastocytosis.
    Nicolosi M; Patriarca A; Andorno A; Mahmoud AM; Gennari A; Boldorini R; Gaidano G; Crisà E
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation.
    Sandow L; Town A; Heinrich MC
    Leuk Res Rep; 2024; 21():100409. PubMed ID: 38273969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis, clinical features, and treatment advances in mastocytosis.
    Pardanani A; Akin C; Valent P
    Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Treatment Options in Mastocytosis.
    Vaes M; Benghiat FS; Hermine O
    Front Med (Lausanne); 2017; 4():110. PubMed ID: 28775983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis.
    Akin C
    Immunol Allergy Clin North Am; 2023 Nov; 43(4):743-750. PubMed ID: 37758410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
    Valent P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
    Akin C; Arock M; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antineoplastic efficacy profiles of avapritinib and nintedanib in
    Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P
    Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Pardanani A; Reichard K; Tefferi A
    Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mastocytosis: pathology, genetics, and current options for therapy.
    Valent P; Akin C; Sperr WR; Mayerhofer M; Födinger M; Fritsche-Polanz R; Sotlar K; Escribano L; Arock M; Horny HP; Metcalfe DD
    Leuk Lymphoma; 2005 Jan; 46(1):35-48. PubMed ID: 15621779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis.
    Veitch S; Radia DH
    Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2023 Jul; 98(7):1097-1116. PubMed ID: 37309222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.
    Tashi T; Deininger MW
    Immunol Allergy Clin North Am; 2023 Nov; 43(4):723-741. PubMed ID: 37758409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.
    Piris-Villaespesa M; Alvarez-Twose I
    Front Pharmacol; 2020; 11():443. PubMed ID: 32346366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.